Active surveillance may be a suitable option for many men with low-risk prostate cancer (PCa), Swedish researchers concluded.
The target BP level of less than 130/80 mm Hg for CKD patients—which is recommended by a Kidney Disease Outcomes Quality Initiative guideline—is not definitively supported by scientific data and could potentially lead to adverse effects.
Deaths from prostate cancer (PCa) fell by almost half after 14 years of biennial screening, according to data from a Swedish study.
A study of testosterone supplementation in older men was terminated after daily application of a testosterone gel was associated with a significantly increased risk of cardiovascular (CV) adverse events.
CHICAGO—Tasquinimod, a novel biologic agent, may significantly slow the rate of disease progression and improve progression-free survival in patients with metastatic castrate-resistant prostate cancer (CRCP), according to a new study presented at the American Society of Clinical Oncology annual meeting.